This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CDK5 | |
|---|---|
| Name | Cyclin-dependent kinase 5 |
| Organism | Homo sapiens |
| Uniprot | P24941 |
| Length | 292 aa |
CDK5 is a proline-directed serine/threonine kinase primarily active in post-mitotic neurons and involved in cytoskeletal dynamics, synaptic function, and signal integration. Discovered through biochemical screens alongside Cyclin-dependent kinase 1 and Cyclin-dependent kinase 2, it stands apart by being regulated by non-cyclin activators and implicated in neurodegenerative and developmental disorders. Research on CDK5 intersects with studies on Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, and neurodevelopmental syndromes.
CDK5's catalytic core shares homology with Protein kinase A, Protein kinase C, Glycogen synthase kinase 3 beta, Mitogen-activated protein kinase 1, and Cyclin-dependent kinase 1, featuring the conserved ATP-binding pocket and activation loop found in the Protein kinase superfamily proteins. Activation requires binding to neuron-specific regulatory subunits such as p35 and p39 derived from transcripts regulated in tissues studied by groups at Harvard Medical School, Stanford University, Massachusetts Institute of Technology, University of Cambridge, and Max Planck Institute laboratories. Proteolytic cleavage of p35 to p25 by Calpain alters the conformation and localization, a mechanism examined in models used at Columbia University, University College London, and Johns Hopkins University. Structural studies employing techniques from X-ray crystallography, Cryo-electron microscopy, and computational methods developed at European Molecular Biology Laboratory and Cold Spring Harbor Laboratory revealed key residues coordinating Mg-ATP and peptide substrates.
CDK5 phosphorylates cytoskeletal and synaptic substrates, modulating actin and microtubule dynamics through targets shared with pathways studied in National Institutes of Health consortia and laboratories at Salk Institute and Broad Institute. It influences axon guidance molecules investigated in Howard Hughes Medical Institute projects and modulates proteins such as tau, neurofilaments, and microtubule-associated proteins linked to work at University of California, San Francisco and Yale University. CDK5 activity affects synaptic vesicle release and neurotransmitter systems implicated in studies from Cold Spring Harbor Laboratory and Imperial College London, interfacing with signaling nodes including N-Methyl-D-aspartate receptor complexes explored by researchers at Weill Cornell Medicine and Rockefeller University. Non-neuronal roles reported in vascular endothelia and immune cells have been pursued at National University of Singapore and Karolinska Institutet.
During cortical development, CDK5 modulates neuronal migration, dendritic arborization, and synaptogenesis—phenomena analyzed in developmental programs at University of California, Berkeley, University of Toronto, and ETH Zurich. Its action intersects with guidance cues characterized in studies of Reelin, Semaphorin, Netrin, and Ephrin pathways investigated at University of Pennsylvania and University of Chicago. CDK5 influences learning and memory circuits probed in behavioral paradigms developed at Princeton University and University of Oxford, and contributes to plasticity mechanisms linked to research on Long-term potentiation and Long-term depression in labs at McGill University and Duke University.
Regulation occurs via association with activators p35 and p39, whose expression is controlled by transcription factors and signaling cascades studied at Cold Spring Harbor Laboratory and Scripps Research. Proteolytic conversion by Calpain to p25 increases half-life and alters localization, a process implicated in models from Scripps Research Institute and University of Pennsylvania. CDK5 is subject to phosphorylation, S-nitrosylation, and ubiquitin-dependent degradation pathways investigated at Imperial College London and University of Michigan Medical School. Crosstalk with kinases such as Cyclin-dependent kinase 1 and Casein kinase 1 and phosphatases studied at Max Delbrück Center modulate substrate specificity and temporal activity patterns.
Aberrant CDK5 signaling is linked to neurodegenerative disorders including Alzheimer's disease, where hyperphosphorylation of tau correlates with findings from National Institute on Aging studies and trials at Mayo Clinic. CDK5 dysregulation contributes to pathologies in Parkinson's disease and Huntington's disease models used at Mount Sinai Hospital and University of Cambridge. Ischemic injury in stroke models implicates CDK5-mediated neuronal death mechanisms examined at University of Sydney and Peking University. Additionally, altered CDK5 activity has been reported in cancer progression and metastasis research at Memorial Sloan Kettering Cancer Center and immune dysfunction studies at Fred Hutchinson Cancer Center.
Small-molecule inhibitors and peptide-based modulators targeting CDK5 have been developed in academic-industry collaborations involving Pfizer, Merck, GlaxoSmithKline, Novartis, and biotechnology firms incubated at Biogen and Genentech. Compounds such as roscovitine, explored by researchers at AstraZeneca and University of Oxford, inhibit CDK family kinases and have been used as tool compounds in preclinical models at National Institutes of Health. Efforts to design selective inhibitors exploit structural insights from European Molecular Biology Laboratory and Structural Genomics Consortium collaborations, while gene therapy and antisense approaches have been trialed at University of Pennsylvania and Stanford University for neurodegenerative indications. Challenges in blood–brain barrier delivery are addressed by nanoparticle platforms developed at MIT and ETH Zurich.